Sebastian Mayer1,2, Boris Gabriel3, Thalia Erbes4,2, Sylvia Timme-Bronsert2,5, Markus Jäger4,2, Gerta Rücker2,6, Franciska Kuf4,2, Jiri Bouda7, Alena Bartakova7, Axel Zur Hausen8, Elmar Stickeler9, Gerald Gitsch4,2, Marc Hirschfeld4,2,10. 1. Department of Obstetrics and Gynecology, Medical Center - University of Freiburg, Freiburg, Germany sebastian.mayer@uniklinik-freiburg.de. 2. Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3. Department of Obstetrics and Gynecology, St. Josefs-Hospital, Wiesbaden, Germany. 4. Department of Obstetrics and Gynecology, Medical Center - University of Freiburg, Freiburg, Germany. 5. Institute of Surgical Pathology, Department of Pathology, Medical Center - University of Freiburg, Freiburg, Germany. 6. Institute for Medical Biometry and Statistics, Medical Center - University of Freiburg, Freiburg, Germany. 7. Department of Obstetrics and Gynecology, Medical Faculty Hospital Pilsen, Charles University Prague, Plzen, Czech Republic. 8. Department of Pathology, Maastricht University Medical Center, Maastricht, the Netherlands. 9. Department of Gynecology and Obstetrics, University Medical Center RWTH Aachen, Aachen, Germany. 10. Institute of Veterinary Medicine, Georg-August-University Goettingen, Goettingen, Germany.
Abstract
BACKGROUND/AIM: The pro-angiogenic Cyr61 protein has been associated with tumorigenesis and cancer progression in different gynecological carcinomas. In this study, we evaluated the potential impact and clinical relevance of Cyr61 expression in patients with primary non-metastatic cervical cancer (CC). PATIENTS AND METHODS: Cyr61 expression was assessed in tissue specimen of 48 patients with primary CC by immunohistochemical analysis. Expression levels were scored and correlated to clinico-pathological factors and outcome data. RESULTS: High Cyr61 expression levels were present in 54.2% of CC tissues. Associations with histological grade (p=0.030), depth of tumor invasion (p=0.007) and GOG score (p=0.027) were observed. Patients who overexpressed Cyr61 displayed an increased death rate (30.8% vs. 18.2%) and a decreased 5-year-survival (76.9% vs. 86.4%). CONCLUSION: Our data indicate a potential functional impact of Cyr61 in development and the progression of CC. The definite tumor-relevant function (suppressive/promoting) of Cyr61 in CC and the prognostic relevance of Cyr61 overexpression has to be evaluated in larger cohorts. Copyright
BACKGROUND/AIM: The pro-angiogenic Cyr61 protein has been associated with tumorigenesis and cancer progression in different gynecological carcinomas. In this study, we evaluated the potential impact and clinical relevance of Cyr61 expression in patients with primary non-metastatic cervical cancer (CC). PATIENTS AND METHODS: Cyr61 expression was assessed in tissue specimen of 48 patients with primary CC by immunohistochemical analysis. Expression levels were scored and correlated to clinico-pathological factors and outcome data. RESULTS: High Cyr61 expression levels were present in 54.2% of CC tissues. Associations with histological grade (p=0.030), depth of tumor invasion (p=0.007) and GOG score (p=0.027) were observed. Patients who overexpressed Cyr61 displayed an increased death rate (30.8% vs. 18.2%) and a decreased 5-year-survival (76.9% vs. 86.4%). CONCLUSION: Our data indicate a potential functional impact of Cyr61 in development and the progression of CC. The definite tumor-relevant function (suppressive/promoting) of Cyr61 in CC and the prognostic relevance of Cyr61 overexpression has to be evaluated in larger cohorts. Copyright